Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The commercial-stage biopharmaceutical company's participation highlights the conference's focus on connecting innovative growth companies with institutional investors and capital providers.
The conference, organized in partnership with B2i Digital, will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend the event, which features main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions.
Alpha Cognition is developing innovative treatments for neurodegenerative diseases such as Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), conditions for which there are currently no approved treatment options. The company's presentation at this prestigious investor forum represents a significant opportunity to advance its clinical programs and secure necessary funding.
We are excited to share our company's story with such a distinguished audience of investors and peers, said Michael McFadden, CEO of Alpha Cognition. The Spartan Capital Conference offers a unique platform to highlight our commercial and pipeline progress, connect with new investors, and strengthen relationships within the capital markets community.
John D. Lowry, Founder and Chief Executive Officer of Spartan Capital Securities, LLC, expressed enthusiasm about Alpha Cognition's participation. Spartan Capital has built its reputation on helping growth companies access the right investors and resources, and this conference is a powerful extension of that mission - bringing together high-quality issuers and serious capital providers under one roof.
David Shapiro, CEO of B2i Digital, emphasized the strategic importance of Alpha Cognition's inclusion in the conference. In collaboration with Spartan Capital's banking team, we invited Alpha Cognition to share their perspective with the investors in attendance. Their participation is part of our broader commitment to connecting investors with a diverse range of growth companies.
The conference represents a critical opportunity for Alpha Cognition to demonstrate the potential of its neurodegenerative disease treatments to a concentrated audience of sophisticated investors. For companies developing therapies for conditions with significant unmet medical needs, such investor conferences can provide essential visibility and access to capital necessary for advancing clinical development programs.
For more information about the conference and registration details, please visit https://spartancapital.com. Additional information about Alpha Cognition's research and development programs can be found at https://www.alphacognition.com/.